Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2(V617F)-myeloproliferative neoplasm

A 62-year-old woman, who had a 16-year history of JAK2(V617F)-mutated myeloproliferative neoplasm (MPN), developed Burkitt leukemia (BL) 16 months after treatment with ruxolitinib to control hydroxyurea-refractory conditions. BL cells were CD10(+), CD19(+), CD20(−), CD34(−), cytoplasmic CD79a(+), an...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Exp Hematop
Egile Nagusiak: Fukutsuka, Katsuhiro, Iioka, Futoshi, Maekawa, Fumiyo, Nakagawa, Miho, Kishimori, Chiyuki, Hayashida, Masahiko, Tagawa, Shunsuke, Akasaka, Takashi, Honjo, Gen, Ohno, Hitoshi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: JSLRT 2021
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265492/
https://ncbi.nlm.nih.gov/pubmed/33994432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3960/jslrt.21001
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak